Navigation Links
Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
Date:2/28/2008

n the United States. Imiquimod and other TLR7 agonists have also demonstrated early clinical activity against other tumor types, including melanoma and chronic lymphocytic leukemia.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the planned scope and trial design of the ANA773 clinical trial, the belief that ANA773 holds promise for the treatment of a range of malignancies, and that it may have utility when combined with targeted agents, therapeutic antibodies and/or chemotherapy, Anadys' ability to identify a dose and schedule for Phase II investigation by the end of this year and the ability to develop ANA773 as a therapy for patients with cancer. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, di
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
2. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
7. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
8. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
11. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased ... Life Science organizations who need document translations. Clients will ... their documents in advance with a selection of nearly 50 ... often a critical factor in clinical and scientific fields, and ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... the rising trend toward miniaturization, carbon nanotubes which ... and possess several unique and very useful properties ... blocks in nanosized electronic and mechanical devices. But it ... tendency to clump together, that make it difficult for ...
... testament to tight integration and ... excellent ... ), a,leader in radiology and medical image and information management solutions,today ... than 100 facilities that use MEDITECH(TM) as their health,information system. AMICAS ...
... device industry to benefit ... trial recruitment efforts, MINNEAPOLIS, May 27 ... has strengthened the,pharmaceutical side of its business with ... a commitment to leveraging differentiators unique,to the medical ...
Cached Biology Technology:Weizmann Institute scientists create new nanotube structures 2AMICAS Announces Integrations at More Than 100 MEDITECH Facilities 2AMICAS Announces Integrations at More Than 100 MEDITECH Facilities 3ThreeWire Expands Presence in the Pharmaceutical Arena 2
(Date:4/24/2014)... --- New research shows that cells are more resilient ... thought. Even when missing critical components, cells can adapt ... way. , In a study published in this week,s ... Michigan State University showed that cells can grow normally ... , "Our genetic information is stored in DNA, which ...
(Date:4/24/2014)... is very pleased to announce that it has assumed ... from the University of Wisconsin. , The ... open-access, peer-reviewed journal that publishes papers on all aspects ... from the molecular to the ecological -- as well ... available to individuals and institutions, and it provides a ...
(Date:4/24/2014)... be improved with new insights into the make-up of ... the Amazon Basin have revealed unprecedented detail of the ... by comparing satellite maps with hundreds of field plots. ... more accurately the amount of carbon each tree can ... schemes, in which trees are given a cash value ...
Breaking Biology News(10 mins):Cell resiliency surprises scientists 2ESA to publish the Journal of Insect Science 2Amazon rainforest survey could improve carbon offset schemes 2
... National Institute of General Medical Sciences, part of the ... Models of Infectious Disease Agent Study for a research ... led by Stephen Eubank, professor. Infectious diseases pose ... worldwide. The Models of Infectious Disease Agent Study (MIDAS) ...
... There might be a time when instead of just drinking ... skin as a way of preventing harmful sun damage or ... caffeine guards against certain skin cancers at the molecular level ... ATR. Scientists believe that based on what they have learned ...
... from NYU Langone Medical Center,s Departments of Orthopaedic Surgery ... used to detect subtle changes in joint cartilage microstructure ... key markers of early osteoarthritis (OA). By using these ... can shift the management of the disease from eventual ...
Cached Biology News:National Institutes of Health renews successful infectious disease research study 2National Institutes of Health renews successful infectious disease research study 3More evidence that caffeine lowers risk of skin cancer 2NYU Langone experts find MRI techniques can detect early osteoarthritis 2
Human Cystatin F MAb (Clone 292103)...
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
TUNEL Apoptosis Detection Kit...
Biology Products: